FORA recent investigation, carried out by the University of Michigansuggests that using a blood test to establish the biological age of the organs of a patient, could help treat them before the first symptoms of the disease appear. The data comes from a study carried out 192 women volunteers.
Although, currently, the Alzheimer’s has no curescience focused on finding certain indicators of the human body that can help predict the onset of the disease. Thus, they found the biomarkerswhich indicate a biological state of a body organ.
According to the study, evaluations during middle age of these Alzheimer’s biomarkers present in the blood can function as early predictors of the posterior cognitive impairment. This allows a early detection of the disease in the patient and prevention before the development of irreversible dementia.
What is Alzheimer’s?
He Alzheimer’s It is a brain disorder that slowly destroys memory and the ability to think of the affected person and, in very advanced cases, affects the ability to carry out even the simpler and more everyday tasks. In addition, patients also experience changes in the behavior and personality.
Although the pathophysiology of Alzheimer’s disease is still not fully known, advances in science in the last decade revealed that the deposit in toxic forms of the amyloid beta protein – who participates in the information transmission between neurons – in the brain causes destruction little by little internal skeletonwhich causes the first symptoms of cognitive impairment. The neurons are damaged and lose the connections to each other and eventually they die.
The World Health Organization (WHO) estimates that, approximately, 60 million people globally They live with Alzheimer’s. This represents the 8.1% of women over 65 years of age and 5.4% of men over 65 years of age.
What does the study reveal about Alzheimer’s?
The study data came from 192 middle-aged women that were observed for 14 yearsthrough the Study on women’s health throughout the Country, carried out by the University of Michigan, among others. Two blood serum biomarkers were analyzed, amyloid beta (Aβ)42, Aβ42/40 ratio and phosphorylated tau181 (p-tau181) and its levels were tracked in the volunteers and then the results of a series of neurological function tests were compared.
Alzheimer.jpg
The finding was that, the highest levels of p-tau181 were directly related to a deterioration cognitive further accelerated and, similarly, the lowest levels of AB 42/40 also with more rapid cognitive decline. The study will now seek to be done on a basis of more extensive patients.
The first conclusions reveal that blood assessments of Alzheimer’s biomarkers, such as those studied, during middle age can yield key data for one early prediction of cognitive decline. Furthermore, the study could lead to less invasive neurological testing methods and more affordable for patients.
Source: Ambito
I am an author and journalist who has worked in the entertainment industry for over a decade. I currently work as a news editor at a major news website, and my focus is on covering the latest trends in entertainment. I also write occasional pieces for other outlets, and have authored two books about the entertainment industry.
